1. Home
  2. AKTX vs ACXP Comparison

AKTX vs ACXP Comparison

Compare AKTX & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Akari Therapeutics plc ADS

AKTX

Akari Therapeutics plc ADS

SELL

Current Price

$7.18

Market Cap

15.4M

Sector

Health Care

ML Signal

SELL

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

SELL

Current Price

$1.04

Market Cap

5.8M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
AKTX
ACXP
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.4M
5.8M
IPO Year
2014
2021

Fundamental Metrics

Financial Performance
Metric
AKTX
ACXP
Price
$7.18
$1.04
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
3
Target Price
★ $25.50
$10.33
AVG Volume (30 Days)
32.2K
★ 101.7K
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.12
$0.90
52 Week High
$29.32
$7.54

Technical Indicators

Market Signals
Indicator
AKTX
ACXP
Relative Strength Index (RSI) 42.25 47.37
Support Level $5.01 $0.95
Resistance Level $9.91 $1.12
Average True Range (ATR) 0.90 0.09
MACD -0.06 0.01
Stochastic Oscillator 24.25 67.29

Price Performance

Historical Comparison
AKTX
ACXP

About AKTX Akari Therapeutics plc ADS

Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: